Lexicon Pharmaceuticals Inc (LXRX)

Currency in USD
1.860
+0.110(+6.29%)
Closed·
1.870+0.010(+0.54%)
·
Trading near 52-week High
Earnings results expected in 0 days
LXRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.7401.860
52 wk Range
0.4801.860
Key Statistics
Prev. Close
1.75
Open
1.75
Day's Range
1.74-1.86
52 wk Range
0.48-1.86
Volume
2.13M
Average Vol. (3m)
3.01M
1-Year Change
263.2103%
Book Value / Share
0.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LXRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.360
Upside
+80.65%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals Inc Earnings Call Summary for Q4/2025

  • Lexicon Pharmaceuticals beat Q4 2025 expectations with EPS of -$0.04 vs. -$0.07 forecast and revenue of $5.5M vs. $3.92M projected.
  • Company achieved 54.1% improvement in net loss per share through cost reductions: R&D expenses down 57.7%, SG&A down 72.8% year-over-year.
  • Stock declined 4.29% to $1.56 in pre-market despite earnings beat, following 385% gain over past year; InvestingPro suggests slight overvaluation.
  • 2026 guidance projects operating expenses of $100M-$110M with focus on cardiometabolic programs and Zynquista resubmission for Type 1 diabetes.
  • CEO highlighted strengthened balance sheet and strategic repositioning; company completed successful capital raise post-year-end to fund development.
Last Updated: 03/05/2026, 09:32 AM
Read Full Transcript
Lexicon investor slides for Q4/2025
Lexicon Q4 2025 slides
Last Update: Mar 05, 2026
See full investor slides

Compare LXRX to Peers and Sector

Metrics to compare
LXRX
Peers
Sector
Relationship
P/E Ratio
−15.7x−2.5x−0.5x
PEG Ratio
−0.20−0.090.00
Price / Book
7.3x5.3x2.6x
Price / LTM Sales
15.8x10.3x3.2x
Upside (Analyst Target)
26.0%92.5%47.6%
Fair Value Upside
Unlock3.3%6.1%Unlock

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.360
(+80.65% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy6.00+222.58%-MaintainMar 12, 2026
H.C. Wainwright
Buy6.00+222.58%4.00MaintainMar 05, 2026
H.C. Wainwright
Buy4.00+115.05%-MaintainSep 11, 2025
H.C. Wainwright
Buy4.00+115.05%-MaintainSep 09, 2025
H.C. Wainwright
Buy4.00+115.05%-MaintainSep 03, 2025

Earnings

Latest Release
Mar 05, 2026
EPS / Forecast
-0.04 / -0.07
Revenue / Forecast
5.5M / 3.92M
EPS Revisions
Last 90 days

LXRX Income Statement

People Also Watch

15.400
UMAC
+10.08%
68.05
HALO
+1.10%
824.01
LITE
-3.37%
142.520
AAOI
-2.64%
66.41
LASR
-0.69%

FAQ

What Is the Lexicon (LXRX) Stock Price Today?

The Lexicon stock price today is 1.860 USD.

What Stock Exchange Does Lexicon Trade On?

Lexicon is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Lexicon?

The stock symbol for Lexicon is "LXRX."

What Is the Lexicon Market Cap?

As of today, Lexicon market cap is 788.050M USD.

What Is Lexicon's Earnings Per Share (TTM)?

The Lexicon EPS (TTM) is -0.139.

When Is the Next Lexicon Earnings Date?

Lexicon will release its next earnings report on Apr 30, 2026.

From a Technical Analysis Perspective, Is LXRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Lexicon Stock Split?

Lexicon has split 1 times.

How Many Employees Does Lexicon Have?

Lexicon has 81 employees.

What is the current trading status of Lexicon (LXRX)?

As of Apr 15, 2026, Lexicon (LXRX) is trading at a price of 1.860 USD, with a previous close of 1.750 USD. The stock has fluctuated within a day range of 1.740 USD to 1.860 USD, while its 52-week range spans from 0.480 USD to 1.860 USD.

What Is Lexicon (LXRX) Price Target According to Analysts?

The average 12-month price target for Lexicon is 3.360 USD, with a high estimate of 6 USD and a low estimate of 1 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +80.65% Upside potential.

What Is the LXRX After Hours Price?

LXRX's last after hours stock price is 1.870 USD, the stock has decreased by 0.010, or 0.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.